Biocodex USA Acquires Totect®, Antidote for Unintended Tissue Damage from Chemotherapy

  Biocodex USA Acquires Totect®, Antidote for Unintended Tissue Damage from
  Chemotherapy

 Totect^® is the Only FDA-Approved Treatment for Anthracycline Extravasation

Business Wire

SAN BRUNO, Calif. -- April 02, 2013

Biocodex USA announced today its acquisition of the oncology supportive care
product, Totect^® from Apricus Biosciences. Totect^® (dexrazoxane HCl) is the
only FDA-approved treatment for anthracycline extravasation, a rare but
debilitating event which has the potential to cause severe tissue damage and
lasting injury. Biocodex USA purchased the asset outright from Apricus, terms
non-disclosed.

“Making a powerful impact within the underserved and emerging discipline of
oncology supportive care, aligns with our fundamental patient-focused values,”
said Marc Rohman, U.S. executive vice president and general manager of
Biocodex North America. “Treating cancer humanely is not solely about saving
lives, it’s also about preserving dignity and the quality of everyday life for
patients. We are particularly excited about Totect^®, an acquisition which
serves as our entry point to defining ourselves as a supportive care
provider.”

Biocodex USA strives to form additional strategic alliances to advance the
vision of building a patient-centric oncology supportive care portfolio.
Biocodex is seeking in-licensing, acquisition or co-development opportunities
with like-minded organizations as they commercialize critical products to
fulfill the unmet needs of cancer patients.

“At Biocodex, we have not only proven our commitment to patients, but also our
ability to thrive and remain profitable in an uncertain economy. In the last
four years, our excellence in sales and marketing has allowed us to achieve
the luxury of uninterrupted year-over-year growth,” said Rohman.

About Totect^®

Totect^® is the only treatment approved by the United States Food and Drug
Administration for anthracycline extravasation. Anthracyclines are cytotoxic
agents among the most common cancer therapies. Chemotherapy extravasation is
an infusion-site error causing the unintended perfusion of surrounding tissue
by the cytotoxic agent. This can cause tissue necrosis (tissue death).
Severity of tissue injury due to chemotherapy extravasation may disrupt the
course of chemotherapy treatment and necessitate painful, disfiguring surgery.
In addition to tissue damage, an anthracycline extravasation may cause
irreversible damage to the nerves, tendons, muscle and joints.

About Oncology Supportive Care

The frequency and severity of the side effects of cancer treatments vary for
every patient and may include: nausea and vomiting, pain, hair loss,
constipation, fatigue, weight loss, and skin disorders. Several innovative
products have been introduced to prevent and manage the adverse events of
cancer and its treatments, enabling patients to tolerate and subsequently
benefit from uninterrupted therapy, while easing the emotional burden for
their caregivers. Oncology supportive care remains an emerging discipline
underserved in healthcare today.

About Biocodex

Biocodex is an independent, family-owned pharmaceutical company founded in
Paris, France, in 1953. The company’s initial focus was gastroenterology, and
specifically, a promising probiotic discovery, Saccharomyces boulardii
(marketed under the brand name Florastor^® in the United States). Biocodex has
partnered with healthcare professionals for 60 years, taking on the mission of
developing meaningful solutions to today’s challenging healthcare problems.
Biocodex has grown into a multinational research and development,
manufacturing and commercial enterprise. The company currently operates in
over 100 countries with subsidiaries in Belgium, Russia, Turkey, Morocco, the
United States, and will be opening the Canadian subsidiary in July, 2013.
Today, Biocodex specializes internationally in the therapeutic areas of
gastroenterology, neuropsychiatry and pain treatment.

For more information visit www.BiocodexUSA.com.

Contact:

Media Contact:
Susan Reilly
The Reilly Group
susanreilly@thereillygroup.com
773-348-3800